---All---
  • ---All---
  • Accession
  • Catalog #

HIF1A AntibodyPeptide Affinity Purified Rabbit Polyclonal Antibody (Pab)

Country
United States
Australia Austria Belgium Brazil Bulgaria Canada China Croatia Cyprus Czech Republic Denmark Estonia Finland France Germany Greece Hungary Iceland India Indonesia Ireland Israel Italy Japan Korea Latvia Lithuania Luxembourg Macedonia Malaysia Malta Netherlands Norway Pakistan Poland Portugal Romania Serbia Singapore Slovakia Slovenia Spain Sweden Switzerland Taiwan Turkey United Kingdom United States Vietnam Others
Ordering Information
Catalog # Size Availability Price  
AP4879d 0.1 mg 400 ul In Stock $ 255.00 Add to cart
AP4879d-ev20 20 ug 100 ul In Stock $ 95.00 Add to cart
  • Specification
  • Citiations : 0
  • Reviews
  • Protocols
  • Backgrounds

HIF1A Antibody - Product info

ApplicationWB, IHC, FC
  • Applications Legend:
  • W=Western Blotting
  • IP=Immunoprecipitation
  • IHC-P=Immunohistochemistry (Paraffin)
  • IF-IC=Immunofluorescence (Immunocytochemistry)
  • F=Flow Cytometry
Primary AccessionQ16665
ReactivityHuman
Concentration0.25 mg/ml
IsotypeRabbit Ig
Calculated MW92670 Da

HIF1A Antibody - Additional info

Gene ID 3091
Other Names
HIF1A; BHLHE78; MOP1; PASD8; Hypoxia-inducible factor 1-alpha; ARNT-interacting protein; Basic-helix-loop-helix-PAS protein MOP1; Class E basic helix-loop-helix protein 78; Member of PAS protein 1; PAS domain-containing protein 8
Target/Specificity
This HIF1A antibody is generated from rabbits immunized with HIF1A recombinant protein.
Dilution
WB~~1:100~500
IHC~~1:10~50
FC~~1:10~50
Format
Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by protein affinity purification.
Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
Precautions
HIF1A Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

HIF1A Antibody - Protein Information

Name HIF1A
Synonyms BHLHE78, MOP1, PASD8
Function
Functions as a master transcriptional regulator of the adaptive response to hypoxia. Under hypoxic conditions, activates the transcription of over 40 genes, including erythropoietin, glucose transporters, glycolytic enzymes, vascular endothelial growth factor, HILPDA, and other genes whose protein products increase oxygen delivery or facilitate metabolic adaptation to hypoxia. Plays an essential role in embryonic vascularization, tumor angiogenesis and pathophysiology of ischemic disease. Binds to core DNA sequence 5'-[AG]CGTG-3' within the hypoxia response element (HRE) of target gene promoters. Activation requires recruitment of transcriptional coactivators such as CREBPB and EP300. Activity is enhanced by interaction with both, NCOA1 or NCOA2. Interaction with redox regulatory protein APEX seems to activate CTAD and potentiates activation by NCOA1 and CREBBP Involved in the axonal distribution and transport of mitochondria in neurons during hypoxia
Cellular Location
Cytoplasm. Nucleus. Note=Cytoplasmic in normoxia, nuclear translocation in response to hypoxia Colocalizes with SUMO1 in the nucleus, under hypoxia
Tissue Location
Expressed in most tissues with highest levels in kidney and heart. Overexpressed in the majority of common human cancers and their metastases, due to the presence of intratumoral hypoxia and as a result of mutations in genes encoding oncoproteins and tumor suppressors

HIF1A Antibody - Related products

AM1934a: HIF1A Antibody (ascites)

AP3707a: Hydroxy-HIF1A- P564 Antibody

AP4776a: HIF1A Antibody (N-term)

AP4776b: HIF1A Antibody (C-term)

AP4879d: HIF1A Antibody

AP7759b: HIF1Alpha Antibody (C-term)

AP7759c: HIF1Alpha Antibody (Center)

RI12452: HIF1A predesign siRNA

BP3707a: Hydroxy-HIF1A-P564 Antibody Blocking Peptide

BP4776a: HIF1A Antibody (N-term) Blocking Peptide

BP4776b: HIF1A Antibody (C-term) Blocking Peptide

BP4776d: HIF1A (HyP564) Antibody Blocking Peptide

BP7759b: HIF1Alpha Antibody (C-term) Blocking Peptide

BP7759c: HIF1Alpha Antibody (Center) Blocking Peptide

AJ1345a: HIF-1 alpha Antibody

HIF1A Antibody - Application data

  • Western blot analysis of HIF1A Antibody (Cat. #AP4879d) in K562 cell line lysates (35ug/lane). HIF1A (arrow) was detected using the purified Pab.

  • HIF1A Antibody (Cat. #AP4879d) IHC analysis in formalin fixed and paraffin embedded lung carcinoma followed by peroxidase conjugation of the secondary antibody and DAB staining. This data demonstrates the use of the HIF1A Antibody for immunohistochemistry. Clinical relevance has not been evaluated.

  • HIF1A Antibody (Cat. #AP4879d) flow cytometric analysis of K562 cells (bottom histogram) compared to a negative control cell (top histogram).FITC-conjugated goat-anti-rabbit secondary antibodies were used for the analysis.

HIF1A Antibody - Research Areas

Abgent welcomes feedback from its customers.

If you have used an Abgent product and would like to share how it has performed, please click on the
"Submit Review" button and provide the requested information. Our staff will examine and post your
review and contact you if needed.

If you have any additional inquiries please email technical services at tech@abgent.com.

Thank you for your support.


Submit

Provided below are standard protocols that you may find useful for product applications.

BACKGROUND

Hypoxia-inducible factor-1 (HIF1) is a transcription factor found in mammalian cells cultured under reduced oxygen tension that plays an essential role in cellular and systemic homeostatic responses to hypoxia. HIF1 is a heterodimer composed of an alpha subunit and a beta subunit. The beta subunit has been identified as the aryl hydrocarbon receptor nuclear translocator (ARNT). This gene encodes the alpha subunit of HIF-1. Overexpression of a natural antisense transcript (aHIF) of this gene has been shown to be associated with nonpapillary renal carcinomas.

REFERENCES

Lee, M.N., et al. J. Natl. Cancer Inst. 102(6):426-442(2010) Mayer, A., et al. Adv. Exp. Med. Biol. 662, 399-405 (2010) Brouwer, E., et al. Clin. Exp. Rheumatol. 27(6):945-951(2009)